Patents by Inventor James D. Pancook

James D. Pancook has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TGF-BETA BINDING ANTIBODIES
    Publication number: 20100136021
    Abstract: The present invention provides very high affinity antibodies, or antigen-binding fragments thereof, that neutralize mature human TGF-?1, TGF-?2, and TGF-?3. The antibodies of the invention are useful for mating cell proliferative disorders in a mammal.
    Type: Application
    Filed: January 26, 2010
    Publication date: June 3, 2010
    Applicant: ELI LILLY AND COMPANY
    Inventors: Bryan Edward Jones, James D. Pancook, Scott William Rowlinson
  • TGF-BETA BINDING ANTIBODIES
    Publication number: 20090155285
    Abstract: The present invention provides very high affinity antibodies, or antigen-binding fragments thereof, that neutralize mature human TGF-?1, TGF-?2, and TGF-?3. The antibodies of the invention are useful for treating cell proliferative disorders in a mammal.
    Type: Application
    Filed: February 6, 2009
    Publication date: June 18, 2009
    Inventors: Bryan Edward Jones, James D. Pancook, Scott William Rowlinson
  • TGF-? binding antibodies
    Patent number: 7494651
    Abstract: The present invention provides very high affinity antibodies, or antigen-binding fragments thereof, that neutralize mature human TGF-?1, TGF-?2, and TGF-?3. The antibodies of the invention are useful for treating cell proliferative disorders in a mammal.
    Type: Grant
    Filed: December 20, 2006
    Date of Patent: February 24, 2009
    Assignee: Eli Lilly and Company
    Inventors: Bryan Edward Jones, James D. Pancook, Scott William Rowlinson
  • Tgf-Beta Binding Antibodies
    Publication number: 20080292638
    Abstract: The present invention provides very high affinity antibodies, or antigen-binding fragments thereof, that neutralize mature human TGF-?1, TGF-?2, and TGF-?3. The antibodies of the invention are useful for treating cell proliferative disorders in a mammal.
    Type: Application
    Filed: December 20, 2006
    Publication date: November 27, 2008
    Inventors: Bryan Edward Jones, James D. Pancook, Scott William Rowlinson
  • Butyrylcholinesterase variant polypeptides with increased catalytic efficiency and methods of use
    Patent number: 7049121
    Abstract: The invention provides twenty-one butyrylcholinesterase variants having increased cocaine hydrolysis activity as well as the corresponding encoding nucleic acids. The invention further provides methods of hydrolyzing a cocaine-based butyrylcholinesterase substrate as well as methods of treating a cocaine-induced condition.
    Type: Grant
    Filed: December 20, 2002
    Date of Patent: May 23, 2006
    Assignee: Applied Molecular Evolution
    Inventors: Jeffry D Watkins, James D Pancook
  • Butyrylcholinesterase variant polypeptides with increased catalytic efficiency and methods of use
    Patent number: 6989261
    Abstract: The invention provides a butyrylcholinesterase variant having increased cocaine hydrolysis activity as well as the corresponding encoding nucleic acid. The invention further provides methods of hydrolyzing a cocaine-based butyrylcholinesterase substrate as well as methods of treating a cocaine-induced condition with the invention variant.
    Type: Grant
    Filed: April 11, 2003
    Date of Patent: January 24, 2006
    Assignee: Eli Lilly and Company
    Inventors: Jeffry D. Watkins, James D. Pancook
  • Butyrylcholinesterase variant polypeptides with increased catalytic efficiency and methods of use
    Publication number: 20040120939
    Abstract: The invention provides a butyrylcholinesterase variant having increased cocaine hydrolysis activity as well as the corresponding encoding nucleic acid. The invention further provides methods of hydrolyzing a cocaine-based butyrylcholinesterase substrate as well as methods of treating a cocaine-induced condition with the invention variant.
    Type: Application
    Filed: April 11, 2003
    Publication date: June 24, 2004
    Applicant: Applied Molecular Evolution
    Inventors: Jeffry D. Watkins, James D. Pancook
  • Butyrylcholinesterase variant polypeptides with increased catalytic efficiency and methods of use
    Publication number: 20040121970
    Abstract: The invention provides twenty-one butyrylcholinesterase variants having increased cocaine hydrolysis activity as well as the corresponding encoding nucleic acids. The invention further provides methods of hydrolyzing a cocaine-based butyrylcholinesterase substrate as well as methods of treating a cocaine-induced condition.
    Type: Application
    Filed: December 20, 2002
    Publication date: June 24, 2004
    Inventors: Jeffry D. Watkins, James D. Pancook
  • Butyrylcholinesterase variant polypeptides with increased catalytic efficiency and methods of use
    Publication number: 20030153062
    Abstract: The invention provides twenty-one butyrylcholinesterase variants having increased cocaine hydrolysis activity as well as the corresponding encoding nucleic acids. The invention further provides methods of hydrolyzing a cocaine-based butyrylcholinesterase substrate as well as methods of treating a cocaine-induced condition.
    Type: Application
    Filed: December 20, 2001
    Publication date: August 14, 2003
    Inventors: Jeffry D. Watkins, James D. Pancook